Carisma Therapeutics Files Q1 2025 10-Q

Ticker: CARM · Form: 10-Q · Filed: May 13, 2025 · CIK: 1485003

Sentiment: neutral

Topics: 10-Q, pharmaceutical, financial-update

Related Tickers: CARM

TL;DR

Carisma Therapeutics (CARM) filed its Q1 2025 10-Q. Financials and operations update.

AI Summary

Carisma Therapeutics Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Sesen Bio, Inc., is involved in pharmaceutical preparations. Key financial data and operational details for the first quarter of 2025 are presented in this filing.

Why It Matters

This filing provides investors with an update on Carisma Therapeutics' financial health and operational status for the first quarter of 2025, crucial for understanding the company's trajectory.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Carisma Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Carisma Therapeutics Inc.?

Carisma Therapeutics Inc. is primarily involved in Pharmaceutical Preparations, as indicated by its SIC code [2834].

When was the company formerly known as Sesen Bio, Inc.?

The company changed its name from Sesen Bio, Inc. on May 16, 2018.

What is the fiscal year end for Carisma Therapeutics Inc.?

The fiscal year end for Carisma Therapeutics Inc. is December 31.

What is the business address of Carisma Therapeutics Inc.?

The business address is 3675 MARKET STREET, SUITE 401, PHILADELPHIA, PA 19104.

What is the SEC file number for Carisma Therapeutics Inc.?

The SEC file number for Carisma Therapeutics Inc. is 001-36296.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Carisma Therapeutics Inc. (CARM).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing